Patents by Inventor Francine M. Gregoire

Francine M. Gregoire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of reducing small, dense LDL particles
    Patent number: 11007162
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 18, 2021
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • METHODS OF REDUCING SMALL, DENSE LDL PARTICLES
    Publication number: 20190298672
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Application
    Filed: October 31, 2018
    Publication date: October 3, 2019
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • Polynucleotides encoding low density lipoprotein receptor
    Patent number: 10323076
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: June 18, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Jeff Lynn Ellsworth, Joseph Beene Bolen, Francine M. Gregoire, Justin Guild
  • POLYNUCLEOTIDE FORMULATIONS FOR USE IN THE TREATMENT OF RENAL DISEASES
    Publication number: 20190054112
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of renal polynucleotides.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 21, 2019
    Inventor: Francine M. GREGOIRE
  • METHODS OF REDUCING SMALL, DENSE LDL PARTICLES
    Publication number: 20160324811
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Application
    Filed: January 13, 2016
    Publication date: November 10, 2016
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • Polynucleotides Encoding Low Density Lipoprotein Receptor
    Publication number: 20160244501
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Applicant: Moderna Therapeutics, Inc.
    Inventors: Jeff Lynn ELLSWORTH, Joseph Beene BOLEN, Francine M. GREGOIRE, Justin GUILD
  • METHODS OF REDUCING SMALL, DENSE LDL PARTICLES
    Publication number: 20100152295
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Application
    Filed: October 15, 2009
    Publication date: June 17, 2010
    Applicant: Metabolex Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION
    Publication number: 20100087468
    Abstract: The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders.
    Type: Application
    Filed: October 7, 2009
    Publication date: April 8, 2010
    Applicant: Metabolex, Inc.
    Inventors: Yan ZHU, Jingyuan Ma, Peng Cheng, Zuchun Zhao, Francine M. Gregoire, Vera A. Rakhmanova
  • Modulators of PPAR and methods of their preparation
    Patent number: 7622491
    Abstract: The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: November 24, 2009
    Assignee: Metabolex Inc.
    Inventors: Yan Zhu, Jingyuan Ma, Peng Cheng, Zuchun Zhao, Francine M. Gregoire, Vera A. Rakhmanova
  • Substituted triazoles as modulators of PPAR and methods of their preparation
    Patent number: 7323480
    Abstract: The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: January 29, 2008
    Assignee: Metabolex, Inc.
    Inventors: Yan Zhu, Jingyuan Ma, Peng Cheng, Zuchun Zhao, Francine M. Gregoire, Vera A. Rakhmanova
  • Nucleic acids encoding a G-protein coupled receptor involved in islet cell signaling
    Publication number: 20040002114
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of human and murine islet cell G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, methods of screening for modulators of islet cell G-protein coupled receptors and methods of treating mammals with modulators of islet cell G-protein coupled receptor activity.
    Type: Application
    Filed: January 6, 2003
    Publication date: January 1, 2004
    Applicant: METABOLEX, INC.
    Inventors: Francine M. Gregoire, Jeffrey D. Johnson, John E. Blume